ODAC Casts 11 to 0 Vote in Favor of Cilta-Cel in R/R Multiple Myeloma
ODAC voted on the risk/benefit ratio of cilta-cel vs standard of care for patients with lenalidomide-refractory multiple myeloma.
ODAC voted on the risk/benefit ratio of cilta-cel vs standard of care for patients with lenalidomide-refractory multiple myeloma.
VivekSubbiah & colleagues delve into the @ASCO #TAPURStudy, shedding light on the importance of targeting ALL #BRAFAlterations, beyond V600E. (Re)-search continues, urging us to push…
In a phase II basket trial, the BRAF inhibitor vemurafenib showed preliminary evidence of efficacy in 13 BRAF-mutant non-melanoma tumor types, including some typically considered…
AbstractThe MAPK pathway is one of the most commonly mutated oncogenic pathways in cancer. Although RAS mutations are the most frequent MAPK alterations, less frequent…
Abstract. The European Society for Medical Oncology defines rare cancers as 5 or fewer cases per 100,000 persons per year. For many rare cancers, no…
PURPOSE Non-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have been identified as oncogenic drivers and can be…
Signal Transduction and Targeted Therapy – Major depressive disorder: hypothesis, mechanism, prevention and treatment
As a part of the Biden Cancer Moonshot, the Department of Veterans Affairs is expanding its Close to Me cancer care program.
DETROIT — Royals rookie left-hander Tim Hill looked in the mirror and hardly recognized himself. A skeleton, he thought. He needed to take a photo,…
Annals of Surgical Oncology –
Help medical professionals keep their jobs while acting on the climate crisis